Please login to the form below

Not currently logged in
Email:
Password:

FDA approves BMS’ Evotaz for HIV

 Combines Reyataz with Gilead’s boosting agent cobicistat  
 FDA building

The US FDA has approved Bristol-Myers Squibb's Evotaz in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Evotaz combines BMS' Reyataz (atazanavir) with Gilead Science's boosting agency cobicistat as part of a once-daily pill to be taken over a 48-week course.

The treatment is the outcome of an agreement made between BMS and Gilead in 2011, when they agreed to develop and market a fixed-dose combination HIV treatment

Murdo Gordon, head of worldwide markets at BMS, commented: “Evotaz increases the possibility of providing HIV suppression by combining reduced pill burden with a low rate of virologic failure and zero protease inhibitor mutations.”

Cobicistat is already a crucial part of several HIV treatments, including Rezolsta/Prezcobix, which pairs the drug with Janssen's Prezista (darunavir), and Gilead's own combination therapy Stribild.

Reyataz is also a successful monotherapy treatment for HIV managing worldwide revenues of more than $1bn for the first nine months of 2014.

BMS is responsible for the manufacturing and sale of the cobicistat-boosted eyataz product and will pay Gilead royalties on sales.

 

Article by
Kirstie Pickering

2nd February 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Shanghai
Biopharma's Future: Made in China
The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise...
Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....

Infographics